摘要
目的:评价前列腺素E1(PGE1)用于治疗冠心病(CHD)患者的效果及其对心率变异性(HRV)的影响。方法:将60例稳定型心绞痛患者随机分为观察组和常规组,常规组给予常规治疗,观察组在其基础上加注前列腺素E1,比较两组患者心脏自主神经病变症状改善情况、治疗前后24小时动态心电图HRV变化情况以及不良反应发生情况。结果:观察组总有效率略高于常规组(90%vs80%);治疗后两组HRV时域指标均有所上升,但观察组治疗后增幅较常规组高(P<0.05);常规组治疗后仅LF/HF较治疗前升高(P<0.05),观察组LF、HF和LF/HF均较治疗前显著升高(P<0.05),与常规组相比,观察组治疗后LF、HF和LF/HF增幅增加更显显著(P<0.05);两组患者均未发生严重不良反应。结论:PGE1能有效改善CHD患者心脏自主神经病变症状及HRV水平,且安全性较高。
Objective：To evaluate the effect of prostaglandin E1 （PGE1） on patients with coronary heart disease（CHD） and its influence on heart rate variability（HRV）. Methods：60 patients with stable angina were randomly assigned to observation group and control group. Regular treatment was put in both groups and PGE1 was added in observation group in addition. The improvement of cardiac autonomic nerve pathological change symptom, change of HRV in ambulatory electrocardiogram 24 hours before and after treatment, and adverse reaction incidence were compared between two groups. Results：The overall efficient of observation group was higher than control group（90%vs80%）. The ascension of HRV time domain indice after treatment were observed in both groups while the increase of observation group was significantly higher than control group （P〈0.05）. LF/HF of control group was higher after treatment （P〈0.05）. LF, HF and LF/HF in observation group were significantly increased after treatment（P〈0.05）, and compared to control group, the increase of the 3 indice in observation group were significantly higher （P〈0.05）. No adverse reaction was observed in both groups. Conclusion：PGE1 could improve cardiac autonomic nerve pathological change symptom and HRV level of CHD patients effectively, with satisfactory safety.
出处
《中国医药导刊》
2013年第11期1826-1827,共2页
Chinese Journal of Medicinal Guide
基金
惠州市惠城区科技局医疗卫生项目
编号:20120801
